Short Summary
Amgen petitions the PTAB to overturn a Director’s denial of institution for an IPR challenging Bristol‑Myers Squibb’s Opdivo dosing patent, arguing the denial misapplied settled‑expectations criteria and ignored European claim abandonments.
Detailed Summary
Amgen Inc. filed a Request for Director Review seeking reversal of the PTAB Director’s discretionary denial to institute an inter partes review of U.S. Patent No. 9,856,320, which covers dosing regimens for the cancer drug Opdivo®. The petition contends that the Director improperly relied on a newly introduced "settled expectations" factor, failed to consider the patent owner’s surrender of nearly identical claims in Europe, ignored a recent disclaimer of a related patent, and overlooked the public interest in accelerating biosimilar availability. Citing prior art such as clinical trial NCT01024231 and European applications, Amgen argues the patent is obvious and that the denial violates statutory and constitutional limits. The request asks the Director to reverse the denial and refer the case to a merits panel.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Amgen Inc. et al. vs Bristol-Myers Squibb Company is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Wealth, Inc.vs--
Wealth, Inc. has filed a Post‑Grant Review petition seeking cancellation of all 20 claims of Vanilla Technologies’ U.S. Patent 12,353,917, alleging ineligibility, obviousness, indefiniteness, and an improper dependent claim. The petition relies on prior‑art references Racanelli, Bateman, Dintenfass, McMillen and Kwak.
Microsoft CorporationvsQomplx LLC
Microsoft has filed an IPR petition challenging 16 claims of Qomplx’s U.S. Patent 12,301,627 covering graph‑based network anomaly detection. The challenger asserts obviousness over prior‑art references Stokes, Crabtree, and Sekar under 35 U.S.C. §103.
Microsoft CorporationvsToutVirtual, Inc.
Microsoft has filed an IPR petition challenging all 20 claims of ToutVirtual’s ‘667 patent covering virtual system management, asserting obviousness over multiple prior‑art references.
Cisco Systems, Inc.vsGOLDEN EYE TECHNOLOGIES LLC
Cisco has filed an IPR petition seeking to invalidate claims 1‑3 and 13‑15 of Golden Eye Technologies' 9,717,037 patent. The challenger argues the claims are obvious over earlier Wi‑Fi standards and patents (Choudhary, Hasty, Chen). The petition requests the Board to institute the review and cancel the challenged claims.
Cisco Systems, Inc.vsGolden Eye Technologies LLC
Cisco has filed an IPR petition seeking to invalidate claims 1‑4 and 9‑11 of Golden Eye’s ’556 Wi‑Fi scanning patent, arguing that the claims are obvious over three earlier patents. The petition emphasizes that the patent was allowed despite acknowledging the same prior‑art concepts.
Pinterest, Inc.vs--
Pinterest has filed an IPR petition challenging all 20 claims of OpenTV’s ’703 patent, asserting that the claims are obvious over prior art such as Orr, Hsu, Lim, and Hervey.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.